Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | EED | O75530 | 1/20 | 0.31 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.31 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32673031 | 1.00 | P2RX7 (0.32) | P2RX7EEDSUZ12EZH2KDM1A | |
| SCHEMBL32672783 | 0.84 | SLC6A2 (0.31) | KDM1AMAOAMAOB | |
| SCHEMBL32672759 | 0.84 | SLC6A2 (0.31) | KDM1AMAOAMAOB | |
| SCHEMBL32673121 | 0.83 | GRIN2D (0.33) | SLC9A1 | |
| SCHEMBL32673039 | 0.83 | GRIN2D (0.33) | SLC9A1 | |
| SCHEMBL32672962 | 0.82 | KDM1A (0.33) | KDM1AMAOAMAOB | |
| SCHEMBL32673185 | 0.82 | KDM1A (0.33) | KDM1AMAOAMAOB | |
| SCHEMBL32673041 | 0.81 | CYP1A2 (0.33) | EEDSUZ12EZH2SLC9A1 | |
| SCHEMBL32672852 | 0.79 | CTSA (0.35) | KDM1AMAOAMAOB | |
| SCHEMBL32673189 | 0.79 | CTSA (0.35) | KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042769-A1 | TRIARYL AGONISTS OF ALPHA-2 ADRENERGIC RECEPTORS | ALCEPTOR THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042769-A1 | TRIARYL AGONISTS OF ALPHA-2 ADRENERGIC RECEPTORS | ADRB2, ADRB1, ADRB3 | P2RX7 321/4885EED 4403/4885SUZ12 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.